Is There an Interplay between Immune Checkpoint Inhibitors, Thromboprophylactic Treatments and Thromboembolic Events? Mechanisms and Impact in Non-Small Cell Lung Cancer Patients.

导出 OA

翻译打印收藏纠错

作者： Federico,Nichetti ^[1] ; Francesca,Ligorio ^[1] ; Emma,Zattarin ^[1] ; Diego,Signorelli ^[1] ; Arsela,Prelaj ^[1] ; Claudia,Proto ^[1] ; Giulia,Galli ^[1] ; Antonio,Marra ^[2] ; Giulia,Apollonio ^[1] ; Luca,Porcu ^[3] ; Filippo,de Braud ^[1] ; Giuseppe,Lo Russo ^[4] ; Roberto,Ferrara ^[1] ; Marina Chiara,Garassino ^[1]

作者单位： Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy. ^[1] Department of Medical Oncology, Istituto Europeo di Oncologia, 20141 Milan, Italy. ^[2] Department of Oncology, IRCCS Istituto di Ricerche Farmacologiche Mario Negri, 20156 Milan, Italy. ^[3] Department of Oncology and Hemato-Oncology, University of Milan, 20122 Milan, Italy. ^[4]

关键词 aspirin immune checkpoint inhibitors immunotherapy non-small cell lung cancer thromboembolic events thromboprophylaxis

DOI 10.3390/cancers12010067

PMID 31881699

发布时间 2020-09-28

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交